2019 年第 5 期 第 14 卷

甲基苯丙胺所致精神障碍男性患者GPR88基因启动子区甲基化水平变化的研究

Methylation of GPR88 gene promoter region in male patients with methamphetamine-induced psychosis

作者：罗涛吕品刘筠余斌

英文作者：

单位：330029南昌，江西省精神病院心理科

英文单位：

关键词：甲基苯丙胺所致精神障碍；DNA甲基化；表观遗传；GPR88基因

英文关键词：

• 摘要：

• 【摘要】目的    探索甲基苯丙胺所致精神障碍（MAP）男性患者GPR88基因启动子区甲基化水平的变化。方法    选取2015年8月至2018年8月江西省精神病院收治的MAP男性患者121例为观察组，同期在本院健康管理中心招募年龄匹配的109名健康男性作为对照组。采用荧光定量聚合酶链反应技术测定GPR88基因启动子区甲基化水平。观察组患者给予利培酮2～6 mg/d治疗，精神病性症状消失后维持治疗6个月后停药，于停药后2周再次测定GPR88基因启动子区甲基化水平，组间组内进行比较。采用Pearson分析探索年龄、开始使用甲基苯丙胺的年龄、使用甲基苯丙胺的总时间与GPR88基因甲基化水平的相关性。结果    观察组中有87例完成研究，GPR88基因启动子区甲基化水平明显高于对照组［（46 124±5 733）比（22 264±5 622）］，差异有统计学意义（t=2.959， P=0.004）；观察组经过治疗，精神病性症状消失后GPR88基因启动子区甲基化水平明显降低，为（33 425±5 797），与治疗前比较差异有统计学意义（t=2.732， P=0.007）。Pearson分析显示年龄、开始使用甲基苯丙胺的年龄、使用甲基苯丙胺的总时间与GPR88基因启动子区甲基化水平相关（r=-0.04、-0.02、0.07，均P<0.05）。结论    GPR88基因启动子区甲基化水平与MAP的精神病性症状存在显著相关。

• 【Abstract】Objective    To explore the changes of methylation level in promoter region of GPR88 gene in male patients with methamphetamine-induced psychosis(MAP). Methods    Between August 2015 and August 2018, 121 male patients with MAP admitted to Mental Hospital of Jiangxi Province were enrolled as observation group; 109 healthy males matched in age were recruited as control group. Methylation of GPR88 gene promoter region was determined by fluorescent quantitative polymerase chain reaction. Patients in observation group were treated with risperidone 2-6 mg/d. After psychiatric symptoms disappearing, risperidone was discontinued 6 months later, and the methylation level of GPR88 gene promoter region was re-measured 2 weeks after withdrawal. Relations of GPR88 gene methylation with age, the age when methamphetamine was first used and the duration time of methamphetamine administration were analyzed by Pearson test. Results    Eighty-seven patients completed the trail in observation group; methylation level of GPR88 gene promoter region in observation group was significantly higher than that in control group［（46 124±5 733） vs （22 264±5 622）］(t=2.959, P=0.004). In MAP patients, GPR88 gene methylation decreased after treatment; the methylation level of GPR88 gene promoter region was (33 425±5 797) after psychiatric symptoms    disappearing, significantly lower than that before treatment(t=2.732, P=0.007). Pearson analysis showed that age, the age when methamphetamine was used and the medication time were correlated with the methylation level of GPR88 promoter region(r=-0.04, -0.02, 0.07, all P<0.05). Conclusion    Methylation of GPR88 promoter region is significantly correlated with the psychiatric symptoms of MAP.